Controllab – the largest provider of Laboratory Quality Control in Brazil and Latin America – earned, at the end of August, more recognition for the production of Certified Reference Materials (MRC): Clinical and Biological Properties with the availability of Qualitative Reference Strains.
In its continuous search to provide the best solutions in laboratory quality control, last year Controllab expanded its initiatives in the microbiological area with the partnership of PHE – Public Health England.
With this partnership, Controllab is committed to produce and supply strains licensed by PHE to meet CLSI, BrCAST – EUCAST, AFNOR, FDA, ISOs, Pharmacopoeias standards, among others. As the company has been accredited since 2016 by Inmetro Cgcre as a Reference Material Producer (PMR 0009), it had already been applying the guidelines of the NBR ISO 17034 standard in the production of the strains.
“We apply the same quality to our production, regardless of the recognition of the material,” explains Joanna Oliveira – production quality manager. “Obtaining accreditation in this property is the seal that we practice international quality standards in our processes”, she continues.
The evaluation for the extension of the scope of the MRC (which already met the Chemical and Physical Properties) took place in March, amid the uncertainties that affected everyone at the beginning of the Covid-19 pandemic. The scope update was published in the last week of August.
“It was an event awaited by the entire company”, highlights Shirley Lima – manager of microbiology. “We were looking forward to sharing with our customers and partners that our Control Strains have become an MRC”, he adds.
Among the factors that have led to this further achievement of the provider, is also the promotion of diversity within the company. “Having a multidisciplinary and extremely collaborative team is a source of pride for us” says Vinicius Biasoli, Controllab’s CEO, who congratulates the entire team on merit.
Obtaining this recognition will not imply additional costs to the laboratories that acquire the strains, which will, from now on, have the MRC seal associated with the material.